News Celgene MS pill can't beat older rival on disability progres... Phase 3 trial meets main efficacy endpoint, but disability progression stats cause concern.
News Drama as Roche's Tecentriq fails in key bladder cancer trial Roche has been shocked by the late-stage trial failure of its immunotherapy Tecentriq in bladder cancer, a setback which could cost it billions if the drug loses its licence.
News Apitope aims to bounce back from MS setback Biotech looks for funding and long-term development partner
News NICE rejects head and neck cancer drug once again NICE rejects German Merck's Erbitux, unsure of effectiveness.
News Debiopharm teams up with Merck KGaA and Pfizer in lung cance... Swiss biotech looks to combine small molecule drug with immunotherapy.
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
